Cardiovascular autonomic neuropathy (CAN) is associated with high risk of sudden cardiac death. In patients with diabetes, diabetic autonomic neuropathy (DAN) indicates an increased incidence of CAN, and is diagnosed based on the early symptoms of neuropathy and autonomic dysfunction. These symptoms may include orthostatic dizziness, gastrointestinal (GI) and genito-urinary (GU) symptoms, and hypoglycemia unawareness or unresponsiveness. In general, a diagnosis of DAN is made only after eliminating other causes of neuropathy. Regardless of what the condition is called, and contrary to the common misperception, autonomic dysfunction is treatable. However, the earlier the autonomic dysfunction is detected, the greater the number of therapy options (see Table 1 ). Therefore, DAN or advanced autonomic dysfunction may be more difficult to treat. In other words, it is easier to correct earlystage autonomic dysfunction compared with advanced-stage autonomic neuropathic damage.
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The main function of the autonomic nervous system (ANS) is to maintain homeostasis, regardless of the conditions. The two main branches of the ANS, the parasympathetic and the sympathetic, can dynamically adjust their input to maintain homeostasis and apparent normalcy even in the face of degraded end-organ function. Often these ANS adjustments result in autonomic imbalance and begin to affect other systems within the body, including the cardiovascular system. This is, in part, the basis for the constellation of symptoms known to degrade quality of life in many chronic diseases. By the time symptoms present as a result of end-organ dysfunction or failure, the ANS has been out of balance for considerably longer.
Unfortunately, early signs of autonomic dysfunction are often not recognized due to two main reasons. First, the current understanding of the effects of the ANS and its interaction with other physiological systems is incomplete.
Second, a reliable clinical tool to measure and monitor the ANS did not exist until recently, when the ability to measure both ANS branches simultaneously and independently was developed commercially (ANSAR Medical Technologies, Inc., Philadelphia, PA). 1, 2 Prior to this, autonomic neuropathy could be clinically diagnosed (orthostatic hypotension, gastroparesis, ShyDrager, POTS, etc.) only at an advanced stage with dramatic symptoms. At this stage, it is usually much too late for anything but treatment of the symptoms. With simultaneous, independent measures of both ANS branches, these patients can be identified even when they are still asymptomatic, or mildly symptomatic, a fairly common situation usually accompanied by fatigue, light-headedness, palpitations, intractable hypertension, etc.
Therapeutic intervention seems to improve outcomes by slowing or halting autonomic decline and the associated disease progression.
The history of non-invasive ANS monitoring in clinical practice is confusing.
Traditionally, it has been based only on measures of heart rate variability (HRV).
Measures of HRV, as defined in the 1996 Circulation standards article, 3 are mixed or incomplete measures of the parasympathetics and the sympathetics. This is not surprising, as HRV by itself, regardless of how much it is dissected, is but one independent measure of a system (the ANS) that contains two 
clinic (e.g. impedance plethysmography) is an appropriate second measure to use in conjunction with HRV. We now have the requisite two measures to fully characterize a two-component system. As a result, the sympathetics and parasympathetics can be measured both independently and simultaneously.
With these two measures at their disposal, physicians are able to individualize treatment based on the patient's physiology. More importantly, physicians can now directly and objectively measure patients' responses to therapy.
To facilitate this insight, medical leadership including the American Diabetes Association (ADA), 4 the American Heart Association, 5 the American Academy symptoms that disrupt quality of life for the average adult (e.g. GI upset, GU dysfunction, sleep difficulties, and orthostasis). If only diabetes led to a disruption of quality of life, the argument could be made that it was the disease; however, since many diseases involve these symptoms, the argument must be made for some underlying condition. Since both ANS branches are significantly involved in all of these functions, when these functions become compromised it is logical that autonomic dysfunction is part of the pathology.
With the ability to differentiate parasympathetic activity from sympathetic activity, and the ability to differentiate both from end-organ symptoms, more information about patients is available. Ultimately, the following questions can be answered:
• Is the patient responding to therapy in such a way as to appropriately limit stress (sympathetic) responses and thereby limit morbidity (i.e. maintain or improve quality of life)?
• Is the patient's heart sufficiently protected as to limit mortality (i.e. maintain longevity)?
• What is the autonomic pathophysiology? and
• What is the best choice of therapy for the individual patient?
We have the ability to measure the parasympathetics and the sympathetics independently and simultaneously, as well as the ability to determine whom to test. The question remains: How do we treat identified patients? Basic ANS therapy is straightforward. There are four autonomic imbalances and eight classes of medications for therapy (see Table 1 ). The four autonomic imbalances are high parasympathetic activity, low parasympathetic activity, high sympathetic activity, and low sympathetic activity.
The choice of a specific therapy option depends on the patient's specific Table 1 ).
A common example in ANS monitoring is the use of a beta-1 adrenergic antagonist or a beta-blocker. With the use of independent, simultaneous measures of parasympathetic and sympathetic activity, physicians have discovered that in patients with chronic disease there is a clinical correlation between symptoms and excess parasympathetic activity during sympathetic challenges such as the Valsalva maneuver or a postural change test. This is especially true among patients with difficult-to-control blood sugar, blood pressure, or hormone levels. These are typically patients with symptoms of parasympathetic excess, including low energy, fatigue, depression-like symptoms, and sleep difficulties, and with symptoms of sympathetic excess, including high heart rate, hypertension, anxiety, or parasympathetic insufficiencies (e.g. gastroparesis). This combination of parasympathetic and sympathetic excess indicates that the ANS 'see-saw' as taught in medical 
When Should Patients Be Tested and How Often?
Autonomic testing should begin when a chronic disease is diagnosed, because when a patient presents with a chronic disease the ANS is already dysfunctional. For example, in the case of type 2 diabetes, testing is recommended by the ADA at the time of diagnosis because the disease is known to have been present for many years without the patient's knowledge.
Medicare will reimburse two tests per year to ensure early detection of additional autonomic pathology. Because the ANS appears to require two to three months to fully adapt to new therapy, depending on the patient's age and ANS status, follow-up testing at the three-month mark is reasonable (and reimbursed) to ensure proper patient response to therapy changes.
As the case study summarized in Figure 2 illustrates, CAN is treatable. An example of a normal patient's resting ANS is presented in the top middle plot. 
